Disclosure: This is an affiliate site. We may earn compensation from partners. Full disclosure | Medical disclaimer
Among the lowest compounded prices — and the subject of an FDA warning letter
$89/mo
Compounded
Cash-pay
August 30, 2026
The FDA issued LumiMeds a warning letter dated September 9, 2025 (MARCS-CMS 716510), stating that its compounded semaglutide and tirzepatide products are misbranded drugs under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act. Read the letter before deciding.
LumiMeds competes almost entirely on price. Its published plans start at $89 a month for compounded semaglutide and $125 a month for compounded tirzepatide on the longest commitments, undercutting nearly everyone in the category.
Those headline numbers require 12-month prepayment. Month-to-month pricing is $189 for semaglutide and $279 for tirzepatide, with three-month bundles at $399 and $649 and mid-length plans in between at roughly $140 to $166 a month.
The important context is regulatory. On September 9, 2025 the FDA issued LumiMeds a warning letter concluding that its compounded semaglutide and tirzepatide products are misbranded drugs under sections 502(a) and 502(bb) of the FD&C Act. That is a matter of public record and anyone considering this provider should read it directly.
LumiMeds dispenses compounded semaglutide and tirzepatide, which are not FDA-approved. The FDA issued LumiMeds a warning letter on September 9, 2025 stating that these products are misbranded drugs under the FD&C Act. This is materially different from the general caveat that applies to all compounded GLP-1s.
Online intake and clinical review by a licensed provider, included in the plan price.
Adults meeting standard GLP-1 criteria as assessed by the reviewing provider.
Licensed providers review intake and prescribe. Ongoing provider involvement beyond initial prescribing is not clearly detailed publicly.
Not publicly listed as a requirement.
Compounding pharmacies. LumiMeds has marketed 503B outsourcing facility sourcing on some plans. Note that the FDA has proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list, which would remove that pathway.
Shipped to your door. Injectable compounded GLP-1s require refrigerated cold-chain handling.
In-platform support. LumiMeds does not publish a phone number prominently.
No separate membership fee published — pricing is presented as all-in plan pricing.
Included in the plan price, which varies dramatically by commitment length.
Long plans are prepaid and auto-renew (the 12-month semaglutide plan renews at $1,068 every 47 weeks). Understand the renewal terms before committing.
No published blanket refund policy. Prepaid long-term plans carry meaningful financial exposure.
Not accepted. Compounded GLP-1s are not covered by insurance.
Reimbursement for compounded, non-FDA-approved medication is uncertain. Check with your plan administrator before assuming eligibility.
Pricing in this review reflects what LumiMeds and named third-party sources published as of August 30, 2026. Telehealth pricing changes frequently — confirm the current figure at checkout before you buy.
We do not recommend this provider ahead of alternatives at similar price points. If you are evaluating it purely on cost, read the FDA warning letter first and weigh it against comparably priced options with no enforcement history.
The FDA warning letter is the defining limitation and it is not a minor procedural matter — the agency concluded the products were misbranded drugs. Combined with 12-month prepaid auto-renewing plans, the financial and regulatory exposure is higher here than at competitors charging only modestly more.
Yes. The FDA issued LumiMeds a warning letter dated September 9, 2025 (MARCS-CMS 716510), concluding that its compounded semaglutide and tirzepatide products are misbranded drugs under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act. The letter is published on the FDA website and we recommend reading it directly.
LumiMeds publishes plans from $89 a month for compounded semaglutide and $125 a month for compounded tirzepatide, but those rates require 12-month prepayment. Month-to-month is $189 for semaglutide and $279 for tirzepatide, with three-month bundles at $399 and $649 respectively.
No. LumiMeds dispenses compounded semaglutide and tirzepatide, which are not FDA-approved. Beyond that general caveat, the FDA has specifically found LumiMeds products to be misbranded drugs in a September 2025 warning letter.
LumiMeds' own published plan terms describe the lowest semaglutide plan as renewing at $1,068 every 47 weeks, and the longest tirzepatide plan renewing at $1,500. Review the renewal terms carefully before prepaying.
On the longest prepaid plans, yes — $89 a month for semaglutide is among the lowest published figures anywhere. On month-to-month pricing at $189, it is not cheaper than all-in providers such as Curex at $149.
That is your decision, but you should make it with the FDA warning letter in front of you. At similar price points there are compounded providers with no enforcement history, and FDA-approved options such as Foundayo now start at $149 a month.
Every pricing and policy claim on this page traces back to one of these sources, checked on August 30, 2026.
Lowest published rate; renews at $1,068 every 47 weeks
Month-to-month rate
Roughly $133/mo equivalent
Renews at $1,500 on the longest plan
Month-to-month rate
Roughly $216/mo equivalent
Verified August 30, 2026. Prices change often — confirm before purchase.
Share your experience with LumiMeds to help others make informed decisions.
This review is for informational purposes only and is not medical advice, a diagnosis, or a treatment recommendation. GLP-1 medications are prescription drugs with serious potential side effects and are not appropriate for everyone. Always consult a qualified healthcare provider before starting, changing, or stopping any medication. Compounded medications are not FDA-approved. The FDA does not evaluate compounded products for safety, effectiveness, or quality. Individual results vary. This page contains affiliate links, and we may earn compensation if you use them.
Date reviewed: August 30, 2026